Search Results | Blood | American Society of Hematology

1-20 of 478

2 3 4 5

Sort by

Sort Order Select

Journal Articles

International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI

Amy S. Ruppert, Jesse G. Dixon, Gilles Salles, Anna Wall, David Cunningham, Viola Poeschel, Corinne Haioun, Herve Tilly, Herve Ghesquieres, Marita Ziepert, Jocelyne Flament, Christopher Flowers, Qian Shi, Norbert Schmitz

Blood (2020) 135 (23): 2041–2048.

DOI: https://doi.org/10.1182/blood.2019002729

Published: 2020

Includes: Supplemental data

Journal Articles

Health Resource Utilization and Costs Associated with the Use of Obinutuzumab-Based Regimens Are Similar to Rituximab-Based Regimens for the First-Line Treatment of Follicular Lymphoma

Tu My To, PhD, Keith L. Dawson, DNP, MS, Anthony S Masaquel, PhD MPH, Arpamas Seetasith, PhD

Blood (2019) 134 (Supplement_1): 4721.

DOI: https://doi.org/10.1182/blood-2019-123408

Published: 2019

Journal Articles

High Risk of Relapse with Intermediate Dose Cytarabine for Consolidation in Young Favorable Risk AML Patients Following Induction with 7+3

Bhaskar Kolla, MBBS, Nurul Aidah Abdul Halim, MBBS, Zohar Sachs, MD PhD, Erica D. Warlick, MD, Daniel J. Weisdorf, MD, Fiona He, MD, Lao Zhentang, MBBS, MRCP

Blood (2019) 134 (Supplement_1): 3432.

DOI: https://doi.org/10.1182/blood-2019-123306

Published: 2019

Journal Articles

High Rate of Exclusion of HIV Infected Patients from Modern Lymphoma Studies: An Analysis of Current United States Therapeutic Trials

Manoj P. Menon, MD, Victor A. Chow, MD, Adam Greenbaum, MD PhD, Ryan C. Lynch, MD, Mazyar Shadman, MD MPH, Andrei Shustov, MD, Stephen D. Smith, MD, Brian G. Till, MD, Yolanda D. Tseng, MD, Chaitra S. Ujjani, MD, Thomas S. Uldrick, MD MS, Edus H. Warren, MD PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 4733.

DOI: https://doi.org/10.1182/blood-2019-127505

Published: 2019

Journal Articles

A Discrete Event Simulation Model to Evaluate the Impact of Treatment Sequences on Long-Term Patient Outcomes in Multiple Myeloma (MM)

Jinan Liu, PhD, Daniel Moldaver, PhD, Xinmei Zhu, PhD, Allen Zhou, BASc, Eric M Maiese, PhD, Sarah Hollmann, M.Biotech

Blood (2019) 134 (Supplement_1): 4737.

DOI: https://doi.org/10.1182/blood-2019-123804

Published: 2019

Journal Articles

Economic Burden of Emergency Room (ER) Visits and Hospitalizations Among Newly Diagnosed Multiple Myeloma (NDMM) Patients in the United States

Eric M Maiese, PhD, Xinmei Zhu, PhD, Bingcao Wu, Yen-Wen Chen, Sikander Ailawadhi, MD

Blood (2019) 134 (Supplement_1): 4715.

DOI: https://doi.org/10.1182/blood-2019-127071

Published: 2019

Journal Articles

Complemental Prognostic Impact of Flow Cytometric and Molecular Quantification of Minimal/Measurable Residual Disease in Acute Myeloid Leukemia

Wolfgang Kern, MD, Manja Meggendorfer, PhD, Claudia Haferlach, MD, Torsten Haferlach, MD

Blood (2019) 134 (Supplement_1): 4657.

DOI: https://doi.org/10.1182/blood-2019-130304

Published: 2019

Journal Articles

Economic Burden of Neurologic Toxicities Associated with Treating Relapsed Refractory Diffuse Large B-Cell Lymphoma in the United States

Michael S Broder, MD MSHS, Qiufei Ma, PhD, Tingjian Yan, PhD, Eunice Chang, PhD, Lamis K. Eldjerou, MD, Yanni Hao, PhD, David Kuzan, MD, Jie Zhang, PhD

Blood (2019) 134 (Supplement_1): 4719.

DOI: https://doi.org/10.1182/blood-2019-122587

Published: 2019

Journal Articles

Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms

Anna B. Halpern, MD, Nicholas P Howard, Megan Othus, PhD, Paul C. Hendrie, MD PhD, Nikita Vashi Baclig, MD MPH, Sarah A Buckley, MD, Mary-Elizabeth M. Percival, MD, Pamela S. Becker, MD PhD, Bart L. Scott, MD, Vivian G. Oehler, MD, Terry B. Gernsheimer, MD, Sioban B. Keel, MD, Johnnie Orozco, MD, Ryan D. Cassaday, MD, Andrei R Shustov, MD, Garrett Hartley, Verna L Welch, PhD MPH, Elihu H. Estey, MD, Roland B. Walter, MD PhD MS

Blood (2019) 134 (Supplement_1): 1317.

DOI: https://doi.org/10.1182/blood-2019-124586

Published: 2019

Journal Articles

A Randomized Trial of EPOCH-Based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatment Interval (DTI) and Pre-Protocol Systemic Therapy on Outcomes

Juan Carlos Ramos, MD BS, Joseph Sparano, MD, Page C. Moore, PhD, Eric Siegel, Jeannette Y Lee, PhD, Erin G. Reid, MD MS, Richard F. Ambinder, MD, Amy Chadburn, MD, Paul G. Rubinstein, MD, Christine Durand, Ethel Cesarman, MD PhD, Lee Ratner, MD PhD, Robert A Baiocchi, MD PhD, David M. Aboulafia, MD, Lawrence D Kaplan, MD, Adam Capoferri, Ronald T. Mitsuyasu, MD, Ariela Noy, MD

Blood (2019) 134 (Supplement_1): 1588.

DOI: https://doi.org/10.1182/blood-2019-129687

Published: 2019

Journal Articles

Combination of Phosphodiesterase 4 (PDE4) Inhibitor Roflumilast and R-CHOP As First-Line Therapy for High-Risk Diffuse Large B Cell Lymphoma Patients

Adolfo E Diaz, MD, Matthew James Butler, MD, Anand Karnad, MD, Ricardo Aguiar, MD PhD

Blood (2019) 134 (Supplement_1): 1592.

DOI: https://doi.org/10.1182/blood-2019-124382

Published: 2019

Journal Articles

Comparative Analysis of Patterns of Infectious Complications of Outpatient Vs. Inpatient Care Following Intensive Induction Chemotherapy for Adults with Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasms

Anna B. Halpern, MD, Nicholas P Howard, Megan Othus, PhD, Paul C. Hendrie, MD PhD, Nikita Vashi Baclig, MD MPH, Sarah A Buckley, MD, Mary-Elizabeth M. Percival, MD, Pamela S. Becker, MD PhD, Bart L. Scott, MD, Vivian G. Oehler, MD, Terry B. Gernsheimer, MD, Sioban Keel, MD, Johnnie Orozco, MD, Ryan D. Cassaday, MD, Andrei R Shustov, MD, Garrett Hartley, Verna L Welch, PhD MPH, Elihu H. Estey, MD, Roland B. Walter, MD PhD MS

Blood (2019) 134 (Supplement_1): 1323.

DOI: https://doi.org/10.1182/blood-2019-123605

Published: 2019

Journal Articles

Clinical Outcome of an Multicentre, Randomized, Phase II Clinical Trial for Patients with Extranodal NK/T Cell Lymphoma Treated By P-Gemox or Aspametdex

Hui-qiang Huang, Gao Yan, Hang Su, Yunhong Huang, Yuhuan Gao, Wang Xiaoxiao, Bai Bing, Yujing Zhang, Liping Su, Xiaoxia Chu, Wenyu Li, MD PhD, Junyi Zhang, Qiaohua Zhang, MD, Liansheng Zhang, Xiaohua Hu, Liqun Zou, Zhiming Li, Wenqi Jiang

Blood (2019) 134 (Supplement_1): 1569.

DOI: https://doi.org/10.1182/blood-2019-123478

Published: 2019

Journal Articles

Real-World Practice Patterns in a Nationwide Cohort of Veterans with Waldenström's Macroglobulinemia

Kelli M Rasmussen, MS, Vikas Patil, MS, Hsu-Chih Chien, PhD MSc, Deborah Kay Morreall, BS, Catherine Li, PhD, Zachary R Burningham, PhD, Brian C Sauer, PhD, Ahmad S Halwani, MD

Blood (2019) 134 (Supplement_1): 5270.

DOI: https://doi.org/10.1182/blood-2019-127738

Published: 2019

Journal Articles

Decitabine Can Improve the Efficacy of Second-Line Chemotherapy in Relapsed or Refractory Diffuse Llarge B Cell Lymphoma

Xudong Zhang, Junxia Hu, Qingjiang Chen, Mingzhi Zhang, MD PhD, Ken H. Young

Blood (2019) 134 (Supplement_1): 5221.

DOI: https://doi.org/10.1182/blood-2019-128424

Published: 2019

Journal Articles

Androgen Receptor Targeting with Enzalutamide for Mantle Cell Lymphoma: Safety and Efficacy

Victor A. Chow, MD, Paul S. Martin, MD, Stephen D. Smith, MD, Brian G. Till, MD, Solomon A. Graf, MD, Kerstin L. Edlefsen, MD, Lindsay M. Hannan, MD MSPH, Elahe A. Mostaghel, MD PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 5254.

DOI: https://doi.org/10.1182/blood-2019-125462

Published: 2019

Journal Articles

Re-Induction and Targeted Conditioning with Anti-CD45 Iodine ( 131 I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial

Blood (2019) 134 (Supplement_1): 5642.

DOI: https://doi.org/10.1182/blood-2019-122776

Published: 2019

Journal Articles

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Peter Westervelt, MD PhD, Jorge E. Cortes, MD, Jessica K. Altman, Meixiao Long, MD, Vivian G. Oehler, MD, Ivana Gojo, MD, Jeanmarie Guenot, PhD, Patrick Chun, MD, Gail J. Roboz, MD

Blood (2019) 134 (Supplement_1): 834.

DOI: https://doi.org/10.1182/blood-2019-129042

Published: 2019

Journal Articles

A Standardized Equation Model of Quality of Life in Myeloproliferative Neoplasms

Robyn M. Scherber, MDMPH, Martin M. Goros, MS, Jonathan Gelfond, MD PhD, Amylou C. Dueck, PhD, Sarah F Christensen, MD, Hans Hasselbalch, MD, Holly L. Geyer, MD, Ruben A Mesa, MD

Blood (2019) 134 (Supplement_1): 2181.

DOI: https://doi.org/10.1182/blood-2019-126803

Published: 2019

Journal Articles

Comparison of Myeloablative (CyTBI, BuCy) Versus Reduced-Intensity (FluBu2TBI400) Peripheral Blood Stem Cell Transplantation in Acute Myeloid Leukemia Patients with Low WT1 Expression Level at Transplant

Silvia Park, GI June MIN, MD, Sung-Soo Park, Seung-Ah Yahng, MD PhD, Young-Woo Jeon, MD PhD, Seung-Hwan Shin, MD PhD, Jae-Ho Yoon, MD PhD, Sung-Eun Lee, MD, Byung-Sik Cho, MD, Ki-Seong Eom, MD PhD, Yoo-Jin Kim, MD PhD, Seok Lee, MD PhD, Chang Ki Min, MD PhD, Seok-Goo Cho, MD PhD, Dong-Wook Kim, Jong-Wook Lee, MD PhD, Hee-Je Kim, MD PhD

Blood (2019) 134 (Supplement_1): 1973.

DOI: https://doi.org/10.1182/blood-2019-128306

Published: 2019

2 3 4 5

NARROW

International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI

Health Resource Utilization and Costs Associated with the Use of Obinutuzumab-Based Regimens Are Similar to Rituximab-Based Regimens for the First-Line Treatment of Follicular Lymphoma

High Risk of Relapse with Intermediate Dose Cytarabine for Consolidation in Young Favorable Risk AML Patients Following Induction with 7+3

High Rate of Exclusion of HIV Infected Patients from Modern Lymphoma Studies: An Analysis of Current United States Therapeutic Trials

A Discrete Event Simulation Model to Evaluate the Impact of Treatment Sequences on Long-Term Patient Outcomes in Multiple Myeloma (MM)

Economic Burden of Emergency Room (ER) Visits and Hospitalizations Among Newly Diagnosed Multiple Myeloma (NDMM) Patients in the United States

Complemental Prognostic Impact of Flow Cytometric and Molecular Quantification of Minimal/Measurable Residual Disease in Acute Myeloid Leukemia

Economic Burden of Neurologic Toxicities Associated with Treating Relapsed Refractory Diffuse Large B-Cell Lymphoma in the United States

Comparison of Outcomes after Early Hospital Discharge (EHD) Following Intensive Induction Vs. Post-Remission Chemotherapy for Adults with Acute Myeloid Leukemia (AML) and Other High-Grade Myeloid Neoplasms

A Randomized Trial of EPOCH-Based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatment Interval (DTI) and Pre-Protocol Systemic Therapy on Outcomes

Combination of Phosphodiesterase 4 (PDE4) Inhibitor Roflumilast and R-CHOP As First-Line Therapy for High-Risk Diffuse Large B Cell Lymphoma Patients

Comparative Analysis of Patterns of Infectious Complications of Outpatient Vs. Inpatient Care Following Intensive Induction Chemotherapy for Adults with Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasms

Clinical Outcome of an Multicentre, Randomized, Phase II Clinical Trial for Patients with Extranodal NK/T Cell Lymphoma Treated By P-Gemox or Aspametdex

Real-World Practice Patterns in a Nationwide Cohort of Veterans with Waldenström's Macroglobulinemia

Decitabine Can Improve the Efficacy of Second-Line Chemotherapy in Relapsed or Refractory Diffuse Llarge B Cell Lymphoma

Androgen Receptor Targeting with Enzalutamide for Mantle Cell Lymphoma: Safety and Efficacy

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

A Standardized Equation Model of Quality of Life in Myeloproliferative Neoplasms

Comparison of Myeloablative (CyTBI, BuCy) Versus Reduced-Intensity (FluBu2TBI400) Peripheral Blood Stem Cell Transplantation in Acute Myeloid Leukemia Patients with Low WT1 Expression Level at Transplant

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only